[ad_1]
 |
The Korea New Drug Development Research Association (Chairman Dong-yeon Kim) announced on the 22nd that it will hold the Korea New Drug Development Awards (KNDA) award ceremony on the 26th at 15: 30 at the Samjeong Hotel Geranium Hall in Seoul.
△ Hanmi Pharm △ Lego Chem Bioscience △ Alteogen △ Olix was selected as the company that won the Technology Export Award in the technology export category.
Hanmi Pharm has developed the treatment of non-alcoholic steatohepatitis ‘Epinofegdeutide (LAPSGLP / GCG)’. Epinofegdeutide is a dual-action treatment that simultaneously activates GLP-1, which helps suppress insulin secretion and appetite, and glucagon, which increases energy metabolism.
Legochem Biosciences has developed ADC candidates and ADC platforms. ADC is an innovative treatment that combines the selectivity of an antibody and the powerful cancer cell killing function of a drug by conjugating an antibody and an anticancer drug with a linker. By precisely delivering the drug to cancer cells without harming normal cells, it can reduce side effects compared to existing anticancer drugs. It is a technology.
Alteogen developed the original technology for human hyaluronidase. The original human hyaluronidase technology (ALT-B4) is a platform technology that converts existing intravenous antibodies or protein drugs into easy-to-use formulations for subcutaneous injection.
Olix developed ‘OLX301A’, a treatment for wet and dry macular degeneration, and ‘OLX301D’, a treatment for subretinal fibrosis and wet macular degeneration. ‘OLX301A’, a treatment for dry and wet macular degeneration (AMD), and ‘OLX301D’, a treatment for subretinal fibrosis and wet macular degeneration, are candidates for ribonucleic acid (RNA) treatment for up to four eye diseases. .
Journalist Minji Kim [email protected]
<저작권자 © 의학신문, 무단 전재 및 재배포 금지>
